february, 2016

25feb10:30 am1:00 pmMeet with… Angel Investors


Event Details

Looking for an angel? …Confused about the process? …Overwhelmed by the diversity of angel investors? You\’re not alone. JLABS is bringing together a cohort of angel investors to speak with the early-stage life sciences community to help you get ahead when it comes to angel money.

Angel investors will be presenting on Thursday, February 25. They will offer insights, lessons learned, and best practices for seeking angel money. You\’ll also learn about the differences between these networks, as well as the key differences between angel investing and traditional venture funding.

For those companies who apply online and receive advance approval, one-on-one meetings with angel investors will provide a private forum to discuss your company.

10:30am | Registration Opens and Networking
11:00am | Presentations
12:00pm | Panel Discussion
12:30pm | Networking Lunch
1:00-4:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 9th.

Participating Representatives:
Richard Anders | Founder, Executive Director, Mass Medical Angels
Eyal Geffen | Managing Partner, Sky Ventures read bio»
Deb Kemper | Managing Director, Golden Seeds
Yaniv Sneor | Founder, Mid Atlantic BioAngels read bio»
[moderator] Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC read bio»

About Sky Ventures:
Sky Ventures Group provides startups with access to the world\’s leading healthcare and life science investors. Our unique investment approach combines the best features of early stage funding and strategic partnerships. Among our members are qualified investors who have extensive experience building and running new ventures, as well as strategic partners from leading corporations and institutions. While we recognize that capital plays a major role, we also understand that a strategic approach is essential to every venture success.
\'EyalSky Ventures\’ Participating Representative: Eyal Geffen | Managing Partner, Sky Ventures
Eyal Geffen has 15 years of demonstrated success in various management and hands on positions. He has had experience with large corporations, coupled with extensive background building and running new ventures and comprehensive knowledge of international markets. As a founder and Managing Partner of Sky Ventures Group, Eyal is responsible for all management and day to day operations.
Connect with Eyal: \'Connect

About Mid Atlantic BioAngels:
Mid Atlantic BioAngels group (MABA), is an angel investor group focused exclusively on new and emerging life science companies. Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels.
MABA places no geographical restrictions or requirements for presenting companies, as long as meaningful and effective post-investment monitoring of these companies can be achieved.
\'YanivMid Atlantic BioAngels\’ Participating Representative: Yaniv Sneor | Founder, Mid Atlantic BioAngels
Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group. MABA also orchestrates regular life science pitching events (1stpitchlifescience.com), which began in NYC and have since expanded to other states. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships. Through his consulting practice (Blue Cactus Consulting), Mr. Sneor assists companies with strategy, execution and technology commercialization.
Connect with Yaniv: \'Connect

Moderator\’s Biography:
\'MarianMarian Nakada, Ph.D. | Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC
Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston. She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics.
Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson\’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.
Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor\’s technologies were competitive with the industry.
Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Connect with Marian: \'Follow \'Connect

$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on February 24th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on February 9th. Your application will be reviewed by each participating angel investor and you will be notified of acceptance by any or all participating networks on February 17th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with… Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA\’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

JLABS @ LabCentral
700 Main Street
Cambridge, MA


(Thursday) 10:30 am - 1:00 pm


JLABS @LabCentral

700 Main St Cambridge, MA 02139